Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer

Phase 3 Completed 200 enrolled Samsung Medical Center

RandomizedParallel-groupOpen-labelTreatment

To assess the optimal sequence of the palliative chemotherapy regimen (DP --\> FOLFIRI vs FOLFIRI --\> DP) in metastatic gastric cancer patients.

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	75 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	150 mg/m2	Intravenous
Subject	Leucovorin	Small molecule	100 mg/m2	Intravenous
Subject	fluorouracil	Small molecule	1500 mg/m2	Intravenous
Background	Atropine	Other / unclassified	0.3 mg	Subcutaneous
Background	Dexamethasone	Small molecule	4 mg	Oral
Background	Mannitol	Diagnostic / imaging agent	70 ml	Intravenous